Aprogen is experiencing a surge in stock prices following the announcement that its subsidiary Aptun has secured global exclusive rights for the immune cell booster GPC-100.
As of the morning of August 26, Aprogen's shares rose by 750 won (30%) to 3,250 won, reaching the upper limit of the price increase.
On this day, Aptun announced that it has signed a contract with GPCRT to obtain global exclusive rights for GPC-100 and its combination therapies. Aptun will pay GPCRT 6.5 billion won and will also provide the original developer, GPC, with an upfront payment of 500 million won and up to 472 billion won in milestone royalties.
GPC-100 is a new drug candidate that has completed Phase 2 clinical trials in the United States. According to the company, the trials were conducted last October at ten institutions in the U.S. involving patients with blood cancers such as multiple myeloma, and results were presented at the American Society of Hematology (ASH) meeting in September of last year. A related paper was published in the journal 'Annals of Hematology' in February of this year.
GPC-100 acts as a mobilizer for blood stem cells, facilitating the movement of immune cells and their progenitors from the bone marrow or tissues into the bloodstream. The company explains that when used in combination with the existing mobilizer G-CSF, it can rapidly mobilize not only blood stem cells but also T cells into the bloodstream within one hour.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.